Open AccessImmunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept
Author(s) -
Michael T. Ou,
Brian J. Boyarsky,
Teresa PoYu Chiang,
Sunjae Bae,
William A Werbel,
Robin K. Avery,
Aaron A.R. Tobian,
Allan B. Massie,
Dorry L. Segev,
Jacqueline M Garonzik-Wang
Publication year - 2021
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000003824
Subject(s) - belatacept , immunogenicity , reactogenicity , medicine , kidney transplantation , population , immunology , vaccination , antibody , transplantation , kidney transplant , environmental health
Belatacept may impair humoral immunity, impacting the effectiveness of SARS-CoV-2 mRNA vaccines in transplant recipients. We investigated immunogenicity after SARS-CoV-2 mRNA vaccines in kidney transplant recipients who are and are not taking belatacept.